CRISPR Therapeutics (NASDAQ:CRSP) gains visibility as biotechnology activity aligns with broader movements across the Nasdaq ...
In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the NRF2 gene with CRISPR technology can reverse chemotherapy resistance in ...
To the research team working to save him, KJ Muldoon was first known only as Patient Eta. But within months, KJ’s name — and ...
Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common illnesses. So far, only 15 people have received the treatment. But, if all ...
Scientists used CRISPR to disable the NRF2 gene, restoring chemotherapy sensitivity in lung cancer cells and slowing tumor growth. The technique worked even when only a fraction of tumor cells were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback